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Salma Butt1,2*, Signe Borgquist2,4, Lola Anagnostaki3, Göran Landberg3 and Jonas Manjer1,2Abstract
Background: The aim of this present study was to examine duration of breastfeeding in relation to the risk of
different subgroups of breast cancer. A prospective cohort, The Malmö Diet and Cancer study, including 14092 parous
women, were followed during a mean of 10.2 years and a total of 424 incident breast cancers were diagnosed.
Methods: Tumours were classified regarding invasiveness, tumour size, axillary lymph node status, Nottingham grade,
tumour proliferation (Ki67), HER2, cyclin D1 and p27, WHO histological type and hormone receptor status. Duration
of breastfeeding was measured using total time of breastfeeding, categorized in quartiles using the lowest as the
reference group (<4.0, ≥4.0- < 8.0, ≥8.0- < 13.0 and ≥13.0 months). Average duration of breastfeeding per child and
breastfeeding duration of the first child were also used as exposures in separate analyses. Relative risks, with 95%
confidence intervals, were obtained using a Cox’s proportional hazards analysis adjusted for potential confounders.
Results: Overall risk for breast cancer was similar in all quartiles of breastfeeding. No strong results regarding
breastfeeding duration and breast cancer subgroups were seen. A few results indicated an association between a
relatively long duration of breastfeeding and tumours with high proliferation (Ki67) and grade III histological grade.
Conclusions: Breastfeeding duration was not associated with breast cancer risk and no strong results were seen with
regard to breast cancer subgroups.
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Several early studies and a recently a large meta-analysis
including data from thirty countries, have shown a negative
association between increasing time of breastfeeding and
the risk of breast cancer [1]. However, a number of studies
have not been able to shown this association as reviewed
by Yang et al. [2]. One reason for these inconclusive
findings may be that breastfeeding only influences the
risk of certain sub-groups of breast cancer. There has been
a limited number of studies investigating breastfeeding
in relation to different breast cancer sub-groups, and only
characteristics such as histological type and estrogen
receptor status have been investigated [3-5].
In all, 17 035 women participated in a prospective
population-based cohort in Malmö, Sweden: The Malmö
Diet and Cancer Study (MDCS). The MDCS collected* Correspondence: salma.butt@med.lu.se
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reproduction in any medium, provided the orinformation on breastfeeding, as well as other reproduct-
ive and environmental factors. During follow-up, 622
women were diagnosed with breast cancer. Tumour tissue
samples were available for about 90% of these women,
which allowed tumour reclassification and further tumour
biological examinations. Tumours were evaluated with
regard to invasiveness, size, axillary lymph node status,
Nottingham grade, tumour proliferation (Ki67), Human
epidermal growth factor receptor 2 (HER2) status, and
expression of cell cycle regulators such as cyclin D1
and p27. Tumours were further examined for WHO
histological type (ductal, lobular, and tubular) and hormone
receptor status; estrogen receptor alpha (ERα), estrogen
receptor beta (ERβ) and progesterone receptor (PgR).
The aim of the present study was to examine breast-
feeding in relation to the risk of breast tumours with
different biological characteristics.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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The Malmö Diet and Cancer Study (The MDCS)
All women born between 1923 and 1950 in Malmö were in-
vited to a prospective cohort study, the MDCS. Between the
years 1991 and 1996, 17 035 women participated [6]. Writ-
ten informed consent was obtained from all participants.
Information on breastfeeding, education, occupation,
marital status, age at menarche, parity, year of each child’s
birth, age at menopause, exposure to oral contraceptives
(OC) (ever/never), current use of hormonal replacement
therapy (HRT), alcohol consumption and smoking habits
were collected using a questionnaire at baseline [7].
Menopausal status was assessed using both medical
records and the questionnaire. A women was considered
postmenopausal: (1) if she had undergone bilateral oo-
phorectomy; or (2) if she had undergone hysterectomy
but not bilateral oophorectomy, and if she was ≥55 years
of age; or (3) if the above criteria were absent and she
affirmed that her menstruations had ceased at least
during the calendar year two years prior to baseline
examination; or (4) if it was unknown whether or not she
had undergone a previous oophorectomy or hysterectomy
and information on menstrual status was missing, and
she was ≥55 years of age. In all 11388 women were
postmenopausal at baseline. A woman was classified as
pre-/perimenopausal if she affirmed that she was still
menstruating, or if her menstruations had ceased less
than two years prior to baseline examinations, or if
information on menstrual status was missing and the
women was <55 years of age at baseline.
Height and weight was measured at baseline by a
trained nurse at the study centre, and Body Mass Index
(BMI) was calculated as kg/m2.
The MDCS and the present analyses were approved
by the Ethical Committee at Lund University (LU 51–90
and Dnr 652/2005).
Breastfeeding and parity
Time of breastfeeding was assessed with the help of a
questionnaire. All participants were asked to fill in the
number of children they had given birth to. Information
on birth years of the children and duration of breast-
feeding was retrieved for the first seven children. No
information on twin pregnancies was available. Parity
was defined as the total number of children that a
women answered she had given birth to.
Mean duration of breastfeeding per child was calculated
as the sum of the months of breastfeeding divided by the
number of children with information on breastfeeding.
Total time of breastfeeding was calculated as mean time
of breastfeeding multiplied with parity. This calculation
was made since time of breastfeeding was limited to
seven children and a small amount of women had eight
or more children (n = 13). Breastfeeding of the first childwas investigated in an additional analysis, as it is likely that
changes during the first pregnancy and following lactation
period may be particularly important with regard to the
differentiation of the breast tissue [8]. Women that had
never breastfed were included in the lowest quartile in all
breastfeeding groups.
Follow-up
All women were followed until 31 December 2004 with
tumour end-points retrieved by record linkage with The
Swedish Cancer Registry (until 31 December 2003). Due
to a delay in central registration, linkage to its regional
branch, The Southern Swedish Regional Tumour Regis-
try, provided tumour-endpoints for the year 2004. Vital
status was obtained from The Swedish Cause-of-Death
Registry until 31 December 2004. A total of 622 incident
breast cancer cases (including invasive and cancer in
situ) were registered during follow-up.
Study population
Out of 17 035 women, 576 had been diagnosed with
breast cancer prior to inclusion in the study, and they
were categorized as prevalent breast cancer cases and
were subsequently excluded from the analyses. A total of
2089 women were nulliparous and hence excluded from
the study population. Yet another 278 had no information
on parity and were also excluded. This gave us a study
population of 14 092 women with 522 incident breast
cancer cases. A total of 57, were cancer in situ (CIS)
and only provided person-years until event, but did not
provide invasive end-points in the analyses for “all
breast cancers”. CIS cases were neither included in the
analyses of specific subgroups, e.g. histology and receptor
status. Ten women with bilateral breast cancer were
excluded as tumour end-points in the analyses due to
difficulties in determining the relevant side to be used
in the analyses of tumour size, axillary lymph nodes,
histopathology and receptor status. A further 31 did
not have sufficient tissue for further analyses. Bilateral
cases and cases with no tumour material did however
provide person-years up until the event. In all 424 tumours
were included in the subgroup analyses (Figure 1).
Histopathological analyses
One senior breast pathologist re-evaluated all invasive
tumours (LA). All tumours were re-evaluated concerning
invasiveness and tumour type was described according
to the WHO classification. The tumours were graded
according to Elston and Ellis, including tubular formation,
nuclear atypia and mitotic index [9]. Further tumour
characteristics were evaluated using the tissue micro-
array technique (TMA). For the construction of tissue
micro array, described elsewhere [10,11] two cores of
0.6 mm from each tumour were taken and arranged in
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Figure 1 Study population (MDCS).
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were performed using specific antibodies, described
previously by Borgquist et al. [10] and tumours were
evaluated according to the nucleus expression of ERα,
ERβ, PgR, Ki67, cyclin D1 and p27. Tumours were dichot-
omized as negative and positive using the categories
0–10% and 11-100% of positive nuclei respectively. HER2
was analyzed using IHC as previously described [10].
HER2 was classified according to the Swedish clinical
practice [12]. As data on HER2 amplification was not
available, HER2 status was based on IHC analyses and
in this study dichotomized into negative (0 and 1+) or
positive cases (2+ and 3+). All arrays were evaluated
independently twice by the same person (SiB) and in
case of discrepancy, a third evaluation was performed
by the same investigator.
Information on tumour laterality, size and lymph node
metastasis were retrieved from medical records and
histopathological reports by one registered nurse.Statistical methods
The main analyses used total duration of breastfeeding as
measurements. Additional analyses used mean duration of
breastfeeding and breastfeeding duration of the first child.
Breastfeeding duration was divided into quartiles. Quartile
cut-offs for breastfeeding were based on the distribution
of all women in the study cohort. Different quartiles of
breastfeeding were compared regarding the distribution
of established and potential risk factors for breast cancer.
Each subject was followed until the event of breast
cancer, death or end of follow- up, 31 December 2004.
The incidence of breast cancer was calculated per 100,000
person-years in different breastfeeding quartiles. Corre-
sponding relative risks of breast cancer were analyzed
using a Cox’s proportional hazards analysis yielding
relative risks (RR) with 95% confidence intervals (CI).
These analyses were subsequently adjusted for potential
confounders; age at baseline, education, socioeconomic
status, marital status, age at menarche, age at first birth,
parity, oophorectomy, age at menopause, oral contraceptive
use, hormone replacement therapy use, bmi, alcohol con-
sumption, smoking and height (categorized in Table 1).
Trend over breastfeeding categories was examined from
the lowest to the highest quartile, excluding the missing
category.
To examine heterogeneity, to test whether effect esti-
mates were similar between for example grade I and grade
III tumours in a certain breastfeeding quartile, adjusted
case-case models using unconditional logistic regression
analysis were used and p-values <0.05 were considered
statistically significant.
Results
Total duration of breastfeeding in relation to risk factors
for breast cancer
Women in the highest quartile of breastfeeding duration
were more often multiparous and younger at first child-
birth, as compared to all other groups. Moreover, women
in the highest quartile were older at menopause, were less
exposed to oral contraceptives and had to a higher extent
never smoked (Table 1). All other factors were evenly
distributed between breastfeeding categories.
Total duration of breastfeeding in relation to risk of
different breast cancer subgroups
The overall risk of breast cancer (i.e. the risk of unilateral
invasive tumours with biological material) was similar in
all breastfeeding groups as compared to the lower quartile
(Table 2). There was a trend towards grade III tumours in
women with higher duration of breastfeeding, however
this association did not reach statistical significance
(Table 2). The risk of high Ki67 expressing tumours was
statistically significantly associated with increased dur-
ation of breastfeeding (Table 3). Women in the lowest
Table 1 Distribution of risk factors in different quartiles of total duration of breastfeeding
Time in months: <4.0 ≥4.0 - <8.0 ≥8.0 - <13.0 ≥13.0 Missing
Total: 14092 n = 2908 n = 3688 n = 3484 n = 3451 n = 561
Column percent (mean and SD in italics)
Age at baseline (years)
Mean (SD) 55.9 (7.7) 56.7 (7.8) 57.6 (7.7) 58.5 (8.1) 57.7 (6.7)
Education (n)
O-level college 74.0 72.7 69.0 65.6 80.6
A-level college 7.7 6.7 7.4 6.2 5.0
University 18.3 20.4 23.2 28.0 13.0
Type of occupation
Manual worker 40.7 39.3 37.9 40.5 45.6
Non-manual worker 51.0 52.9 53.6 49.7 47.1
Employer-self-employed 7.3 7.1 7.5 8.3 5.5
Married/cohabiting
No 32.5 30.2 27.5 28.8 35.5
Yes 67.5 69.8 72.5 71.2 64.2
Age at menarche
≤12 23.6 21.3 21.6 22.2 22.5
>12 to <15 53.2 54.8 52.9 51.8 47.1
≥15 22.7 23.2 25.1 25.5 27.1
Parity
1 54.9 30.5 14.1 1.2 40.1
2 35.1 55.7 59.5 41.6 36.5
≥3 10.0 13.9 26.4 57.2 23.4
Age at first childbirth
≤20 17.0 19.7 18.8 22.3 19.4
>20 to ≤25 38.1 41.6 42.1 43.1 34.9
>25 to ≤30 29.7 28.2 29.4 26.5 28.3
>30 15.1 10.4 9.7 8.1 15.9
Bilateral oophorectomy
No 98.7 98.4 98.6 98.7 98.8
Yes 1.3 1.6 1.4 1.3 1.2
Age at menopause
Pre-/perimenopausal 39.3 36.5 31.4 30.0 26.0
≤45 14.5 12.2 11.6 11.3 15.0
>45 to <53 34.7 36.4 40.0 39.9 43.1
≥53 10.2 13.1 15.6 17.4 12.5
Exposure to OC (ever/never)
No 47.3 45.7 49.3 53.5 52.8
Yes 52.6 54.2 50.7 46.5 46.7
Exposure to HRT*
No 79.2 79.7 79.9 82.8 81.7
ERT 8.0 7.5 8.4 7.8 6.0
PRT 0.5 0.3 0.2 0.3 0.0
CHRT 12.0 12.0 11.1 8.8 12.1
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Table 1 Distribution of risk factors in different quartiles of total duration of breastfeeding (Continued)
Height
Mean (SD) 163.5 (6.0) 163.8 (6.0) 163.6 (5.9) 163.4 (6.1) 162.8 (6.2)
Body mass index
Mean (SD) 25.5 (4.4) 25.3 (4.5) 25.3 (4.2) 25.7 (4.4) 26.0 (4.8)
Alcohol consumption
Nothing last year (teetotaler) 10.9 9.2 10.3 13.8 17.5
Something last year (not last month) 12.1 11.4 12.0 12.2 13.7
Something last month 76.8 79.3 77.6 73.8 67.6
Smoking
Never 38.2 40.6 45.4 49.9 44.4
Current 33.2 30.6 26.5 23.0 33.9
Ex 28.5 28.8 28.1 27.1 21.7
Percentages do not always add up to 100% due to missing. *Current in peri- and postmenopausal women n = 10288.
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ductal type of breast tumour, however this results was
not statistically significant (Table 4).
Average duration of breastfeeding
Women in the lowest quartile of average duration of
breastfeeding were younger at baseline and were more
often pre-/perimenopausal at breast cancer diagnosis as
compared to all other groups (Additional file 1: Table S1).
The relative risks for average duration of breastfeeding
were similar to relative risks of total duration of breast-
feeding. The risk of having grade III tumours were statisti-
cally significant for women in the highest quartile and
the trend for having grade III tumours with increasing
time of breastfeeding duration reached statistical signifi-
cance (Additional file 1: Table S2). Moreover, no higher risk
for tubular type was seen in any breastfeeding category
(Additional file 1: Table S4).
Breastfeeding duration of first child
The analyses of breastfeeding of first child in relation to
risk factors for breast cancer showed that women in the
highest quartile were more likely to have had at later first
childbirth as compared to the other breastfeeding groups.
All other risk factors were distributed as for total duration
of breastfeeding (Additional file 1: Table S5). All relative
risks for breastfeeding of the first childbirth in relation
to risk of different breast cancer subgroups were similar
to those related to total duration of breastfeeding and
average duration of breastfeeding (Additional file 1: Table
S6-S8). There was a statistically significant increased risk
of having high expression of cyclin D1 with increasing
duration of breastfeeding (Additional file 1: Table S7).
Discussion
The aim of this study was to investigate breastfeeding in
relation to the risk of different breast cancer subtypesand could not find any strong results. There was a trend
towards more grade III tumours and high Ki67 expression
with increasing duration of breastfeeding. However a
lot of markers were tested and the quartile risks were not
statistically significant for grade and Ki67 when studying
total duration of breastfeeding.
Methodological considerations
Information on breastfeeding was retrieved from a ques-
tionnaire provided at baseline examinations where all
women were 44 years or older, thus unlikely to have
additional children following baseline. A previous study
has confirmed self-reported breastfeeding to be highly
accurate [13], hence we consider this information to be
valid. A limitation of this study is that the questionnaire did
not allow for a distinction between different breastfeeding
patterns. That is, some women may have reported the time
they were exclusively breastfeeding, whilst others may
have filled in total duration of breastfeeding. There may
also be secular trend in breastfeeding patterns, as the
recommendations for exclusive/partial breastfeeding
have changed over time in Sweden [14]. Today, Sweden
is a country with high rate of women breastfeeding for
at least six months [14], yielding a study population
that is most likely affected by these patterns. There is
still no established “best way” of defining the amount of
breastfeeding. Most previous studies have used ever/
never breastfeeding as exposure. In the present study,
there were 680 women (4.8%) who reported that they had
never breastfed. When the present data was re-analyzed
using this categorization, there was no statistically signifi-
cant association between overall breast cancer risk and
ever breastfeeding (adjusted relative risk =1.14: 0.70-1.88)
as compared to never. Indeed, we consider it more valu-
able to investigate total time of breastfeeding in relation to
different breast cancer characteristics in order to see if
there was a threshold.
Table 2 Risk of breast cancer subgroups defined by clinico-pathological markers in relation to total duration of
breastfeeding
Tumour subgroup Breastfeeding total in months Number of cases Incidence/100000 RR RR*
Invasive
breast cancer** <4.0 80 270 1.00 1.00
≥4.0 - <8.0 108 288 1.07 (0.80 - 1.42) 1.04 (0.77 - 1.40)
≥8.0 - <13.0 109 304 1.12 (0.84 - 1.49) 1.09 (0.80 - 1.48)
≥13.0 103 293 1.08 (0.81 - 1.45) 1.10 (0.78 - 1.54)
Missing 24 399 — —
Total 424 294 p-trend: 0.56 p-trend:0.45
CIS
<4.0 9 30 1.00 1.00
≥4.0 - <8.0 19 51 1.67 (0.76 - 3.70) 1.90 (0.84 - 4.30)
≥8.0 - <13.0 13 36 1.20 (0.51 - 2.81) 1.40 (0.57 - 3.46)
≥13.0 13 37 1.22 (0.52 - 2.86) 1.59 (0.60 - 4.21)
Missing 3 50 — —
Total 57 40 p-trend:0.98 p-trend:0.48
Size ≤20 mm#
<4.0 55 186 1. 00 1.00
≥4.0 - <8.0 80 214 1.15 (0.82 - 1.62) 1.12 (0.79 - 1.60)
≥8.0 - <13.0 69 192 1.03 (0.72 - 1.47) 0.99 (0.68 - 1.45)
≥13.0 85 241 1.30 (0.93 - 1.82) 1.29 (0.87 - 1.92)
Missing 15 249 — —
Total 304 211 p-trend:0.21 p-trend:0.24
Size >20 mm
<4.0 25 84 1.00 1.00
≥4.0 - <8.0 27 72 0.85 (0.50 - 1.47) 0.84 (0.48 - 1.47)
≥8.0 - <13.0 39 109 1.28 (0.78 - 2.12) 1.28 (0.75 - 2.20)
≥13.0 18 51 0.61 (0.33 - 1.11) 0.65 (0.33 - 1.27)
Missing 9 150 — —
Total 118 82 p-trend:0.36 p-trend:0.63
Axillary lymph
node neg# <4.0 27 91 1.00 1.00
≥4.0 - <8.0 32 85 0.94 (0.56 - 1.56) 0.91 (0.54 - 1.54)
≥8.0 - <13.0 34 95 1.04 (0.63 - 1.72) 0.99 (0.56 - 1.70)
≥13.0 31 88 0.97 (0.58 - 1.62) 0.90 (0.50 - 1.64)
Missing 5 83 — —
Total 129 89 p-trend:0.99 p-trend:0.82
Axillary lymph
node pos <4.0 53 179 1.00 1.00
≥4.0 - <8.0 72 192 1.07 (0.75 - 1.53) 1.05 (0.73 - 1.51)
≥8.0 - <13.0 71 198 1.10 (0.77 - 1.57) 1.08 (0.73 - 1.57)
≥13.0 71 202 1.13 (0.79 - 1.61) 1.18 (0.78 - 1.79)
Missing 19 316 — —
Total 286 198 p-trend: 0.52 p-trend:0.30
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Table 2 Risk of breast cancer subgroups defined by clinico-pathological markers in relation to total duration of
breastfeeding (Continued)
Grade I#
<4.0 27 91 1.00 1.00
≥4.0 - <8.0 37 99 1.08 (0.66 - 1.78) 1.01 (0.61 - 1.69)
≥8.0 - <13.0 28 78 0.85 (0.50 - 1.45) 0.78 (0.44 - 1.38)
≥13.0 28 80 0.87 (0.51 - 1.48) 0.87 (0.47 - 1.61)
Missing 7 116 — —
Total 127 88 p-trend:0.42 p-trend:0.71
Grade II
<4.0 33 111 1.00 1.00
≥4.0 - <8.0 47 125 1.12 (0.72 - 1.75) 1.05 (0.67 - 1.66)
≥8.0 - <13.0 53 148 1.32 (0.85 - 2.03) 1.15 (0.73 - 1.83)
≥13.0 46 131 1.17 (0.75 - 1.83) 0.99 (0.60 - 1.64)
Missing 12 199 — —
Total 191 132 p-trend:0.40 p-trend:0.97
Grade III##
<4.0 20 67 1.00 1.00
≥4.0 - <8.0 23 61 0.91 (0.45 - 1.66) 1.00 (0.54 - 1.85)
≥8.0 - <13.0 28 78 1.15 (0.65 - 2.05) 1.43 (0.77 - 2.66)
≥13.0 29 82 1.22 (0.69 - 2.16) 1.74 (0.89 - 3.41)
Missing 5 83 — —
Total 105 73 p-trend:0.34 p-trend:0.051
*Adjusted for age at baseline (continuous), education, socioeconomic status, marital status, age at menarche, age at first birth, parity, oophorectomy, age at
menopause, oral contraceptive use, hormone replacement therapy use, bmi, alcohol consumption, smoking and height.
**All cases with unilateral invasive breast cancer with tissue samples available for examination.
#Reference group in heterogeneity analyses. ##Heterogeneity: p = 0.031.
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to The Swedish Cancer Registry. This is a nation-wide
registry and all cancer cases in Sweden are to be reported
to this registry. This registry has previously been validated
in Malmö and the completeness was 99% regarding breast
cancer [15].
Women with prevalent breast cancer were not included
in the analyses since these women most likely are cause to
bias. Women with a prevalent breast cancer at baseline
are more likely to decline participation in a prospective
study making them subject to selection bias. Moreover,
a recent study has shown reduced lactation in these
women [16].
The mammography screening program was fully initi-
ated in Malmö 1990 and during 1991 – 1996 the average
participation rate was 65% [17,18]. This could have led
to over diagnosis of breast cancer, but in our study only
incident invasive breast cancers were included in the
subgroup analyses. Further tumour classification with
regard to the biomarkers, were analyzed using the TMA
technique which is a well-documented method for tumour
tissue screening and two cores are considered to be suf-
ficient in order to get a representative sample [19,20].The IHC data was not retrieved in medical records
since laboratory analyses were subject to changes over
this period of time and hence analyzing all tumours
again within TMAs by one pathologist was considered
more accurate.
Women in the MDCS were probably selected towards
higher socioeconomic groups and the participants in
the MDCS had a higher incidence of breast cancer as
compared to the rest of the female population in Malmö
[6]. However, absolute risks may not be applicable to the
background population, but, as we had a large variation
in exposure within our sample, we consider that it is still
possible to make internal comparisons, thus calculating
valid relative risks.
In this study it is important to consider chance findings.
There is a risk of a type I error due to the many analyses
in this study and our previous study on parity and risk
for different breast cancer subgroups was carried out in
the same cohort MDCS [21]. No correction for multiple
testing was made. As for type II errors, due to few individ-
uals in some analyses, the confidence intervals were wide
and the statistical power was relatively low which may
have lead to a type II error in some comparisons. And it is
Table 3 Risk of breast cancer subgroups defined by immunohistochemical markers in relation to total duration of
breastfeeding
Tumour subgroup Breastfeeding total in months Number of cases Incidence/100000 RR RR*
Ki67 low
(≤10%)# <4.0 54 182 1.00 1.00
≥4.0 - <8.0 76 203 1.11 (0.78 - 1.57) 1.06 (0.74 - 1.51)
≥8.0 - <13.0 72 201 1.09 (0.77 - 1.56) 1.01 (0.69 - 1.47)
≥13.0 58 165 0.90 (0.62 - 1.31) 0.82 (0.53 - 1.25)
Missing 11 183 — —
Total 271 188 p-trend:0.54 p-trend:0.44
Ki67 high
(>10%) <4.0 17 57 1.00 1.00
≥4.0 - <8.0 21 56 0.98 (0.51 - 1.85) 1.02 (0.53 - 1.96)
≥8.0 - <13.0 26 72 1.25 (0.68 - 2.31) 1.39 (0.72 - 2.67)
≥13.0 30 85 1.48 (0.82 - 2.69) 1.88 (0.94 - 3.76)
Missing 7 116 — —
Total 101 70 p-trend:0.11 p-trend:0.03
HER2 (0-1+)#
<4.0 57 192 1.00 1.00
≥4.0 - <8.0 78 208 1.08 (0.77 - 1.52) 1.02 (0.72 - 1.45)
≥8.0 - <13.0 84 234 1.21 (0.86 - 1.69) 1.12 (0.78 - 1.61)
≥13.0 73 207 1.07 (0.76 - 1.52) 1.07 (0.72 - 1.59)
Missing 19 499 — —
Total 311 216 p-trend:0.58 p-trend:0.44
HER2 (2 + −3+)
<4.0 9 30 1.00 1.00
≥4.0 - <8.0 9 24 0.80 (0.32 - 2.01) 1.02 (0.39 - 2.65)
≥8.0 - <13.0 11 31 1.02 (0.42 - 2.46) 1.40 (0.53 - 3.69)
≥13.0 11 31 1.03 (0.43 - 2.49) 1.35 (0.46 - 3.97)
Missing 1 17 — —
Total 41 28 p-trend:0.79 p-trend:0.59
Cyclin D1 low
(≤10%) # <4.0 54 182 1.00 1.00
≥4.0 - <8.0 82 219 1.20 (0.85 - 1.69) 1.15 (0.81 - 1.64)
≥8.0 - <13.0 73 203 1.11 (0.78 - 1.58) 1.05 (0.72 - 1.53)
≥13.0 73 122 1.14 (0.80 - 1.62) 1.06 (0.71 - 1.60)
Missing 13 216 — —
Total 295 205 p-trend:0.65 p-trend:0.77
Cyclin D1 high
(>10%) <4.0 14 47 1.00 1.00
≥4.0 - <8.0 14 37 0.79 (0.37 - 1.65) 0.84 (0.39 - 1.78)
≥8.0 - <13.0 24 67 1.38 (0.72 - 2.68) 1.56 (0.77 - 3.19)
≥13.0 20 57 1.19 (0.60 - 2.36) 1.61 (0.73 - 3.56)
Missing 6 100 — —
Total 78 54 p-trend:0.29 p-trend:0.10
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Table 3 Risk of breast cancer subgroups defined by immunohistochemical markers in relation to total duration of
breastfeeding (Continued)
P27 low
(≤10%) # <4.0 21 71 1.00 1.00
≥4.0 - <8.0 41 109 1.55 (0.91 - 2.62) 1.56 (0.91 - 2.67)
≥8.0 - <13.0 31 86 1.22 (0.70 - 2.12) 1.21 (0.68 - 2.18)
≥13.0 35 99 1.40 (0.82 - 2.41) 1.35 (0.73 - 2.50)
Missing 7 116 — —
Total 135 94 p-trend:0.47 p-trend:0.61
P27 high
(>10%) <4.0 48 162 1.00 1.00
≥4.0 - <8.0 53 141 0.87 (0.59 - 1.29) 0.83 (0.55 - 1.24)
≥8.0 - <13.0 65 181 1.11 (0.76 - 1.61) 1.04 (0.70 - 1.56)
≥13.0 53 151 0.93 (0.63 - 1.37) 0.93 (0.59 - 1.46)
Missing 11 183 — —
Total 230 159 p-trend:0.95 p-trend:0.73
*Adjusted for age at baseline (continuous), education, socioeconomic status, marital status, age at menarche, age at first birth, parity, oophorectomy, age at
menopause, oral contraceptive use, hormone replacement therapy use, bmi, alcohol consumption, smoking and height.
#Reference group in heterogeneity analyses.
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group analyses, and socioeconomic status might have
an impact on breastfeeding pattern. Thulier et al. have
reviewed variables associated with breastfeeding and
concluded that higher educated and married women,
tend to breastfeed their children for longer periods [22].
The relationship between increased risk of unfavourable
breast cancer characteristics and time of breastfeeding
could be measure of the association between socio-
economic status and breast cancer subgroups. In the
MDCS, there was information available on education,
type of occupation and marital status/cohabiting and
all multivariate analyses were adjusted for these possible
confounders. Hence, socioeconomic status should not
have affected the results of these analyses. It has previously
been shown that women in lower socioeconomic classes
have a lower attendance in mammography screening as
compared to women in higher socioeconomic classes [17].
This could possibly lead to detection bias, as women in
higher socioeconomic classes would more likely have
their breast cancer detected earlier; hence more likely
have breast cancer with less aggressive characteristics
and this would lead to a spurious association between
breastfeeding and less aggressive breast cancer tumours.
As the results in the present study were in the opposite
direction, it makes such an association/detection bias
unlikely.
Previous studies
The breast cancer characteristics Ki67 and grade have
to our knowledge not been investigated with regard
to breastfeeding previously. Most previous studies onbreastfeeding and breast cancer markers, have investigated
histological type and hormone receptor status. One previ-
ous study found increasing total time of breastfeeding
protective against ductal type of breast cancer [5] opposite
the non-significant findings in our study. Ursin et al. found
total duration of breastfeeding to be protective against
ER + PR + and ER-PR- tumours [5], and yet another
found breastfeeding for more than six months to be
protective against triple-negative breast tumours [4].
These findings were not confirmed in this study.
Potential explanations
Breastfeeding reduces lifetime ovulatory menstrual cycles
[23] i.e. reducing the impact of hormone levels present
during normal menstrual cycles [24] and by specifically
reducing the progesterone exposure [25]. This may explain
the finding in previous studies of a reduced risk of breast
cancer in women who had breastfed. It is possible to
hypothesize that an environment with relatively low
levels of estrogen/progesterone may develop certain kind
of tumour sub-groups, i.e. hormone independent tumours
which in most cases are prognostically unfavourable
tumours. We could in this study there not find any sta-
tistically significant association between breastfeeding
and ER- tumours. Moreover breastfeeding stimulate
the production of prolactin, a hormone that has been
reported to have tumour promoting effects [26]. The
potential relation between breastfeeding, prolactin and
breast cancer is, however complex. Even if prolactin
levels are high during lactation, it has been reported
that among non-lactating women, prolactin levels in
blood are relatively low in women with a previous long
Table 4 Risk of breast cancer subgroups defined by type and receptor status in relation to total duration of
breastfeeding
Tumour subgroup Breastfeeding total in months Number of cases Incidence/100000 RR RR*
Ductal#
<4.0 59 199 1.00 1.00
≥4.0 - <8.0 74 197 0.99 (0.70 - 1.39) 0.99 (0.70 - 1.41)
≥8.0 - <13.0 74 206 1.03 (0.73 - 1.45) 1.04 (0.72 - 1.51)
≥13.0 79 224 1.12 (0.80 - 1.58) 1.20 (0.81 - 1.78)
Missing 12 199 — —
Total 298 207 p-trend:0.45 p-trend:0.26
Lobular
<4.0 15 51 1.00 1.00
≥4.0 - <8.0 21 56 1.11 (0.57 - 2.15) 0.95 (0.48 - 1.88)
≥8.0 - <13.0 23 64 1.27 (0.66 - 2.43) 1.02 (0.51 - 2.04)
≥13.0 14 40 0.79 (0.38 - 1.63) 0.65 (0.29 - 1.45)
Missing 9 150 — —
Total 82 57 p-trend:0.63 p-trend:0.44
Tubular
<4.0 4 13 1.00 1.00
≥4.0 - <8.0 10 27 1.97 (0.62 - 6.29) 2.09 (0.64 - 6.89)
≥8.0 - <13.0 7 20 1.43 (0.42 - 4.89) 1.59 (0.43 - 5.91)
≥13.0 6 17 1.26 (0.36 - 4.47) 1.56 (0.37 - 6.70)
Missing 2 33 — —
Total 29 20 p-trend:.1.00 p-trend:0.75
ERα neg ≤10%#
<4.0 9 30 1.00 1.00
≥4.0 - <8.0 12 32 1.05 (0.44 - 2.50) 1.16 (0.48 - 2.83)
≥8.0 - <13.0 13 36 1.18 (0.50 - 2.75) 1.38 (0.55 - 3.47)
≥13.0 15 43 1.40 (0.61 - 3.19) 1.61 (0.60 - 4.35)
Missing 1 17 — —
Total 50 35 p-trend:0.38 p-trend:0.30
ERα pos >10%
<4.0 61 206 1.00 1.00
≥4.0 - <8.0 85 227 1.10 (0.79 - 1.53) 1.06 (0.75 - 1.48)
≥8.0 - <13.0 88 245 1.19 (0.86 - 1.64) 1.13 (0.79 - 1.60)
≥13.0 80 227 1.10 (0.79 - 1.54) 1.09 (0.75 - 1.61)
Missing 20 332 — —
Total 334 232 p-trend:0.52 p-trend:0.47
ERβ neg ≤10%#
<4.0 29 98 1.00 1.00
≥4.0 - <8.0 38 101 1.04 (0.64 - 1.68) 1.04 (0.63 - 1.70)
≥8.0 - <13.0 44 123 1.26 (0.79 - 2.01) 1.26 (0.76 - 2.09)
≥13.0 40 114 1.16 (0.72 - 1.87) 1.20 (0.69 - 2.09)
Missing 9 150 — —
Total 160 111 p-trend:0.40 p-trend:0.32
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Table 4 Risk of breast cancer subgroups defined by type and receptor status in relation to total duration of
breastfeeding (Continued)
ERβ pos >10%
<4.0 33 111 1.00 1.00
≥4.0 - <8.0 41 109 0.98 (0.62 - 1.54) 0.95 (0.59 - 1.53)
≥8.0 - <13.0 40 111 0.98 (0.62 - 1.55) 0.93 (0.57 - 1.53)
≥13.0 33 94 0.84 (0.52 - 1.35) 0.80 (0.46 - 1.40)
Missing 9 150 — —
Total 156 108 p-trend:0.48 p-trend:0.62
PgR neg ≤10%#
<4.0 42 142 1.00 1.00
≥4.0 - <8.0 49 131 0.92 (0.61 - 1.39) 0.91 (0.59 - 1.38)
≥8.0 - <13.0 50 139 0.98 (0.65 - 1.48) 0.96 (0.62 - 1.49)
≥13.0 49 139 0.98 (0.65 - 1.48) 1.01 (0.63 - 1.63)
Missing 9 150 — —
Total 199 138 p-trend:0.98 p-trend:0.90
PgR pos >10%
<4.0 28 94 1.00 1.00
≥4.0 - <8.0 40 107 1.12 (0.69 - 1.82) 1.13 (0.69 - 1.86)
≥8.0 - <13.0 43 120 1.25 (0.78 - 2.02) 1.30 (0.78 - 2.16)
≥13.0 38 108 1.14 (0.70 - 1.85) 1.24 (0.70 - 2.17)
Missing 10 166 — —
Total 159 110 p-trend:0.55 p-trend:0.29
*Adjusted for age at baseline (continuous), education, socioeconomic status, marital status, age at menarche, age at first birth, parity, oophorectomy, age at
menopause, oral contraceptive use, hormone replacement therapy use, bmi, alcohol consumption, smoking and height.
#Reference group in heterogeneity analyses.
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itself may be able to produce prolactin and this would
probably lead to locally increased levels which are not
detectable in ordinary blood samples [28]. The potential
relationship between breast cancer subgroups and pro-
lactin will however need to be studied in experimental
studies, in order to investigate this further.
Generally, factors associated with an increased risk
of breast cancer, e.g. HRT [10] and obesity [29] have
been associated with prognostically relatively favorable
breast tumours. Even if this study did not find any
association of breastfeeding and reduced risk of breast
cancer, it may be possible to hypothesize that the few
associations between breastfeeding duration and ag-
gressive breast cancer characteristics may reflect the
same mechanism. It is possible to hypothesize that
reproductive factors that are protective against breast
cancer may also promote tumours that are non-hormone
dependent and hence tumours that grow more autono-
mous. This should give rise to more aggressive charac-
teristics when studying breast cancer subgroups with
regard to reproductive factors as exposures. However, the
biological mechanism behind this hypothesis has still to
be identified.Conclusions
Breastfeeding duration was not associated with breast
cancer risk and no strong results were seen with regard
to breast cancer subgroups.
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